PHARMACOPOEIAL DISCUSSION GROUP

CORRECTION

CODE: Q-03/04 NAME: UNIFORMITY OF CONTENT/MASS (Correction of the sign-off document Rev. 2 signed on 4 November 2015)

Lines 27-33: Addition to the following to the global text: [FOLLOWING

PARAGRAPH NOT ACCEPTED BY THE UNITED STATES PHARMACOPEIA]

Alternatively, products listed in item (4) above that do not meet the 25 mg/25% threshold limit may be tested for uniformity of dosage units by Mass Variation instead of the Content Uniformity test if the concentration relative standard deviation (RSD) of the drug substance in the final dosage units is not more than 2%, based on process validation data and development data, and if there has been regulatory approval of such a change. The concentration RSD is the RSD of the concentration per dosage unit (w/w or w/v), where concentration per dosage unit equals the assay result per dosage unit divided by the individual dosage unit weight. See the RSD formula in Table 2.

In addition, other editorial corrections were made to ensure consistency with revision 1 signed off on 9 November 2010.

For previous changes related to local and non-harmonized attributes, also see revision 1 signed off 9 November 2010 and the revised cover pages signed off 15 June 2011 and 6 November 2013.

Date:

26 Od 2016

Signatures:

European Pharmacopoeia

C.Viella

Q.O.

Japanese Pharmacopoeia

Hamilio Olcude for Mismoon Tomada

CHTHERNE SIETUAN United States Pharmacopeia

Oct. 26, 2016.

UNIFORMITY OF DOSAGE UNITS

To ensure the consistency of dosage units, each unit in a batch should have a drug substance content within a narrow range around the label claim. Dosage units are defined as dosage forms containing a single dose or a part of a dose of drug substance in each dosage unit. The uniformity of dosage units specification is not intended to apply to solutions, suspensions, emulsions, or gels in unit-dose containers intended for local action following external, cutaneous administration.

The term "uniformity of dosage unit" is defined as the degree of uniformity in the amount of the drug substance among dosage units. Therefore, the requirements of this chapter apply to each drug substance being comprised in dosage units containing one or more drug substances, unless otherwise specified elsewhere in this Pharmacopeia.

The uniformity of dosage units can be demonstrated by either of two methods, Content Uniformity or Mass Variation (see Table 1). The test for Content Uniformity of preparations presented in dosage units is based on the assay of the individual content of drug substance(s) of a number of dosage units to determine whether the individual content is within the limits set. The Content Uniformity method may be applied in all cases.

The test for Mass Variation is applicable for the following dosage forms:

(1)	Salutions enclosed in unit-dose containers and into soft capsules;
(2)	Solids (including powders, granules, and sterile solids) that are packaged in single-unit containers and contain no active or inactive added substances;
(3)	Solids (including sterile solids) that are packaged in single-unit containers, with or without active or inactive added substances, that have been prepared from true solutions and freeze-dried in the final containers and are tabeled to indicate this method of preparation; and
(4)	Hard capsules, uncoated tablets, or film-coated tablets, containing 25 mg or more of a drug substance comprising 25% or more, by weight, of the desage unit or, in the case of hard capsules, the capsule contents, except that uniformly of other drug substances present in lesser proportions is demonstrated by meeting the requirements for Content Uniformity.

The test for Content Uniformity is required for all dosage forms not meeting the above conditions for the Mass Variation test.

[FOLLOWING PARAGRAPH NOT ACCEPTED BY THE UNITED STATES PHARMACOPEIA]

Alternatively, products fisted in item (4) above that do not meet the 25 mg/25% threshold limit may be tested for uniformity of dosage units by Mass Variation instead of the Content Uniformity test if the concentration relative standard deviation (RSD) of the drug substance in the final dosage units is not more than 2%, based on process validation data and development data, and if there has been regulatory approval of such a change. The concentration RSD is the RSD of the concentration per dosage unit (w/w or w/v), where concentration per dosage unit equals the assay result per dosage unit divided by the individual dosage unit weight. See the RSD formula in Table 2.

Table 1. Application of Content Uniformity (CU) and Mass Variation (MV) Tests for Dosage Forms Dose & Ratio of Drug Substance ≥25 mg and ≥25% <25 mg or <25% Dosage Forms Subtype Uncoated ΜV CU Tablets Film MV CΠ Coated Others CU CŲ Hard ΜV CU Suspension, emulsion, Capsules Soft СV or gel CU Solutions ΜV MV Single component ΜV MV Solution freeze-dried in final container Solids in single-unit containers Multiple components ΜV ΜV Others Cυ CU Solutions enclosed in unit-dose containers ΜV ΜV Others—Dosage forms not addressed by the other categories in this table including but not limited to suppositories, transdermal systems (patches) and semisolid preparations applied cutaneously and intended for systemic distribution of the drug substance CU

CONTENT UNIFORMITY

Select not less than 30 units, and proceed as follows for the dosage form designated.

Where different procedures are used for assay of the preparation and for the Content Uniformity test, it may be necessary to establish a correction factor to be applied to the results of the latter,

Solid Dosage Forms
Assay 10 units individually using an appropriate analytical method. Calculate the acceptance value (see *Table 2*).

Liquid or Semi-Solid Dosage Forms

Assay 10 units individually using an appropriate analytical method. Carry out the assay on the amount of well-mixed material that is removed from an individual container in conditions of normal use, and express the results as delivered dose, Calculate the acceptance value (see *Table 2*).

Calculation of Acceptance Value

Calculate the acceptance value by the formula:

in which the terms are as defined in Table 2.

Variable	Definition	Conditions	Value
\overline{X}	Mean of individual contents $(\chi_1, \chi_2,, \chi_p)$, expressed as a percentage of the label claim	Sofianois	Agina
X 1, X 2,, X 8	Individual contents of the dosage units tested, expressed as a percentage of the label claim		
n	Sample size (number of units in a sample)		
k	Acceptability constant	If n = 10, then	2.4
		If n = 30, then	2.0
s	Sample standard deviation		$\left[\frac{\sum\limits_{i=1}^{n}(\chi_{i}-\overline{\chi})^{2}}{n-1}\right]^{\frac{1}{2}}$
RSD	Relative standard deviation (the sample standard deviation expressed as a percentage of the mean)		100s/ X
M (case 1) to be applied whe T ≤101,5	n Reference vatue	If 98.5% ≤ X ≤101.5%, then	$M = \overline{X} (AV = ks)$
		If \overline{X} <98.5%, then	M = 98.5% (AV = 98.5 - \overline{X} + ks)
		If \overline{X} >101.5%, then	M = 101.5% (AV= $\overline{X} - 101.5 + ks$)
M (case 2) to be applied whe T >101.5	n Reference value	If 98.5 $\leq \overline{X} \leq$ T, then	$M = \overline{X}$ (AV=ks)
		If \overline{X} <98,5%, then	M =98.5% (AV = 98.5 - \overline{X} + ks)
		If $\overline{\chi}$ >T, then	$(AV = \frac{M}{X} - T + ks)$
Acceptance value (AV)			General formula: M – X + ks
			(Calculations are specified above for the different cases.)
L1	Maximum allowed acceptance value		L1 = 15.0 unless otherwise specified
L2	Maximum allowed range for deviation of each dosage unit lested from the calculated value of M	On the tow side, no dosage unit result can be less than 0.75M, while on the high side, no dosage unit result can be greater than 1.25M, (This is based on an L2 value of 25.0.)	L2 = 25.0 unless otherwise specified

Variable	Definition	Conditions	 Value:
T :	Target content per dosage unit at the time of manufacture, expressed as a percentage of the label claim. Unless otherwise stated, T is 100.0%, or T is the manufacturer's approved target content per dosage unit.		

MASS VARIATION

 Carry out an assay for the drug substance(s) on a representative sample of the batch using an appropriate analytical method. This value is result A, expressed as percentage of label claim (see Celculation of Acceptance Value). Assume that the concentration (weight of drug substance per weight of dosage unit) is uniform. Select not less than 30 dosage units, and proceed as follows for the dosage form designated.

Uncoated or Film-Coated Tablets

Accurately weigh 10 tablets individually. Calculate the content, expressed as percentage of label claim, of each tablet from the mass of the individual tablet and the result of the assay. Calculate the acceptance value.

Hard Capsules

Accurately weigh 10 capsules individually, taking care to preserve the identity of each capsule. Remove the contents of each capsule by a suitable means. Accurately weigh the emptied shells individually, and calculate for each capsule the net mass of its contents by subtracting the mass of the shell from the respective gross mass. Calculate the drug substance content of each capsule from the mass of the individual capsule and the result of the assay. Calculate the acceptance value.

Soft Capsules

Accurately weigh 10 intact capsules individually to obtain their gross masses taking care to preserve the identity of each capsule. Then cut open the capsules by means of a suitable clean, dry cutting instrument such as scissors or a sharp open blade, and remove the contents by washing with a suitable solvent. Allow the occluded solvent to evaporate from the shells at room temperature over a period of about 30 minutes, taking precautions to avoid uptake or loss of moisture. Weigh the individual shells, and calculate the net contents. Calculate the drug substance content in each capsule from the mass of product removed from the individual capsules and the result of the assay. Calculate the acceptance value.

Solid Dosage Forms Other Than Tablets and Capsules

Proceed as directed for Hard Capsules, treating each dosage unit as described therein. Calculate the acceptance value.

Liquid Dosage Forms

Accurately weigh the amount of liquid that is removed from each of 10 individual containers in

122	conditions of normal us	e. If necessary, co
123	Calculate the drug subs	tance content in e
124	individual containers an	d the result of the
125		
126	Cal	culation of Ac
127 128	Calculate the acceptance	e value se choum
129	the dosage units are re	
	tile dosage dilits alete	praced with the ii
1 39		
	1/1 1/21 ···· 1/2 n	= indivi
_	χ ₁ , χ ₂ ,, χ _n W ₁ , W ₂ ,, W _n	≥ Indivi
	A	= conte
	Tr'	= mear (w,,
132 133		
134		CRITERIA
135	Apply the following crite	

136

137 138 139

140

141

142 143

144

empute the equivalent volume after determining the density. each container from the mass of product removed from the e assay. Calculate the acceptance value.

cceptance Value

in Content Uniformity, except that the individual contents of individual estimated contents defined below.

X1. X2 Xn	individual estimated contents of the dosage units tested, where $y_0 = w_0 \times A/\overline{\mu}^{\nu}$
w ₁ , w ₂ ,, w _h	Individual masses of the dosage units tested
A :	content of drug substance (% of label claim) obtained using an appropriate snalytical method
<u> </u>	mean of individual masses (w ₁ , w ₂ ,, w _n)

wise specified.

Solid, Semi-Solid, and Liquid Dosage Forms

The requirements for dosage uniformity are met if the acceptance value of the first 10 dosage units is less than or equal to L1%. If the acceptance value is greater than L1%, test the next 20 dosage units, and calculate the acceptance value. The requirements are met if the final acceptance value of the 30 dosage units is less than L1%, and no individual content of the dosage unit is less than [1 - (0.01)(L2)]M nor more than [1 + (0.01)(L2)]M in the Calculation of Acceptance Value under Content Uniformity or under Mass Variation. Unless otherwise specified, L1 is 15.0 and L2 is 25.0.